Analyst Ratings for [NTRA] Natera, Inc.

3/13/25	Initiated	Outperform	X
NTRA Natera RBC Capital Mkts
$251
1/23/25	Initiated	Overweight	X
NTRA Natera Barclays
$200
6/3/24	Resumed	Buy	X
NTRA Natera Jefferies
$142
4/8/24	Resumed	Buy	X
NTRA Natera Craig Hallum
$117
2/20/24	Downgrades	Strong Buy Outperform	X
NTRA Natera Raymond James
$68 $85
12/29/23	Reiterated	Buy	X
NTRA Natera BTIG Research
$75 $85
12/14/23	Initiated	Buy	X
NTRA Natera Guggenheim
$70
12/13/23	Initiated	Outperform	X
NTRA Natera Wolfe Research
$70
11/13/23	Upgrades	Outperform Strong Buy	X
NTRA Natera Raymond James
$68
9/28/23	Initiated	Mkt Perform	X
NTRA Natera Bernstein
$48
7/5/23	Resumed	Overweight	X
NTRA Natera JP Morgan
$85
5/5/23	Initiated	Buy	X
NTRA Natera UBS
$76
1/18/23	Upgrades	Mkt Perform Outperform	X
NTRA Natera Raymond James
$58
8/25/22	Initiated	Outperform	X
NTRA Natera Credit Suisse
$70
4/25/22	Initiated	Overweight	X
NTRA Natera Stephens
$54
3/8/22	Initiated	Buy	X
NTRA Natera Goldman
$90
1/6/22	Resumed	Overweight	X
NTRA Natera Piper Sandler
$110
10/15/21	Resumed	Outperform	X
NTRA Natera Cowen
$150
6/15/21	Initiated	Mkt Perform	X
NTRA Natera Raymond James
5/25/21	Initiated	Overweight	X
NTRA Natera Wells Fargo
$110
1/28/21	Initiated	Buy	X
NTRA Natera Truist
$143
10/5/18	Initiated	Neutral	X
NTRA Natera JP Morgan
$26
7/5/18	Reiterated	Overweight	X
NTRA Natera Piper Jaffray
$18 $21

NTRA Natera, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).